Cartherics Pty Ltd’s Post

#Article: The recent acquisition of ImmunoGen, Inc. by AbbVie , which followed the earlier acquisition of Seagen by Pfizer , has brought renewed attention to #antibodydrugconjugates (#ADCs), highlighting their potential in #cancertherapy. This development serves as an opportunity for companies to reflect on the progress within the ADC field and consider its implications for the future of cell therapies. In this article, Dr Ian Nesbit provides a brief overview of the history of ADCs, exploring their evolution and what they can teach us about advancing #cancer treatments. The aim is to offer insights into the challenges and opportunities that lie ahead for ADCs and cell therapies, shedding light on lessons that may shape the cell therapy space. Read more from.pharmaphorum 👇🏽 https://lnkd.in/dFkWivGe

🎉Congratulations to Indapta Therapeutics! Check out these abstracts at the Society for Immunotherapy of Cancer (SITC) meeting. #cellulartherapy #allogeneic #NKcells

Several biotech companies are harnessing the power of natural killer cells in oncology and autoimmune diseases, potentially positioning them as a strong competitor to CAR-T cell therapies. “The advantage of NK cells over a T-cell approach is that NK cells can kill the target cell without causing that runaway cytokine release syndrome,” says Dr. Fred Aslan, president and CEO of Artiva Biotherapeutics. https://lnkd.in/eTasuxFi 

I am delighted to share the announcement of a #collaboration that I have initiated and will be leading on behalf of my client OregonTherapeutics trough my service Lab2BIOTECH. This collaboration involves the analysis of the #preclinical package of Oregon Therapeutics' lead product, XCE853, by Lantern Pharma Inc. (Nasdaq: LTRN) Pharma's #AI based RADR® platform, in order to identify the best clinical positioning of this #drug candidate for #Cancer patient's and further progress toward clinics together.  Please see the press release below. --- Personal notes: This is AI as I like it: no buzzwords, concrete analysis of huge datasets and literature points to leverage smarter strategies in #drugdevelopment and improve patient's impact. This collaboration is also a good illustration of my vision on how best to develop assets for startups. Licensing a drug candidate is not a final step at the end of a development plan. It's an ongoing process, starting from day one of project management, and requires open-mindedness, seeking out opportunities and collaborating with potential licensees to build trust and improve product-market fit with payers' expectations, while driving R&D forward.  Tip for founders: surround yourself!

Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges: The global oncology landscape is on the brink of transformation, with cancer cases expected to rise sharply, particularly in lower-income countries, where the number of new cases could soar to 32 million annually by 2050. This growing demand for cancer … Continue reading → #Business #FinancialMarket #HealthMedicine #US

J&J discontinues late-stage study for bladder cancer drug The drug, TAR-200, was being tested in combination with an experimental antibody drug in patients with muscle-invasive bladder cancer (MIBC) who did not undergo a surgical procedure to remove the bladder and nearby tissues, compared to patients who received concurrent chemoradiotherapy. #bladdercancer I #experimentaldrug I #mid_stage_study I #clinical_trials I #cancer_recurrence I #chemoradiation I Johnson & Johnson Read more: https://lnkd.in/gXMcQDMY

Check out Prime Therapeutics' Oncology Insights article from Simone Ndujiuba discussing a new treatment for small cell lung cancer! This monthly article is always full of quality information and engaging insights.

GlobalData Healthcare considers the growth of chimeric antigen receptor (CAR)-T therapy, a type of #immunotherapy that modifies patient's T-cells to destroy cancer. On our Insights page, read how a prominent biotech employed Judi for Eligibility and Judi for Adjudication on a pivotal Phase 2 CAR-T #oncology #clinicaltrial. Judi.io

🚨BioWire is a weekly newsletter uncovering the latest biotech innovations. This edition gives briefs on revolutionary weight loss drugs, unexpected hurdles in cancer immunotherapy trials, strides in AI-powered drug discovery, and pioneering organoid research. 🧬💡 What are your thoughts on these innovations shaping our future? #biotechnology #AI #Science #medicine #cancer #innovation https://lnkd.in/g_w_T99z

HER2-Targeted Treatments for NSCLC: Introducing Zongertinib: Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy. #finance #pharmacy #lifesciences